Journal of Pharmaceutical Policy and Practice最新文献

{"title":"Evaluation of the implementation and the associated operating costs of a medicine regulatory harmonisation model in Africa: the case of ZaZiBoNa, a SADC work-sharing initiative.","authors":"S Dube-Mwedzi, F Suleman","doi":"10.1080/20523211.2025.2490565","DOIUrl":"https://doi.org/10.1080/20523211.2025.2490565","url":null,"abstract":"<p><strong>Background: </strong>To improve the access to and affordability of medicines, countries in the Southern African Development Community (SADC) established ZaZiBoNa, a medicine regulatory harmonisation initiative. Studies have evaluated the initiative's technical and operational efficiencies and effectiveness. This study evaluated ZaZiBoNa from project implementation and cost perspectives, at the 5-year mark, to establish a business case for further investment.</p><p><strong>Methods: </strong>A quantitative and desk review were undertaken. Two surveys, one with 7 National Regulatory Authorities (NRAs) that participated in the initiative in the initial 5 years were conducted and the other with 40 pharmaceutical companies who submitted applications in the same period were recruited to share their perceived experiences and expectations with the collaborative initiative.</p><p><strong>Results: </strong>All 7 NRAs agreed the initiative had generally achieved its objectives and participation was beneficiary. As of June 2022, the 7 NRAs had registered 152 of the 235 (64.7%) products assessed during the study period, with a median time from joint assessment recommendations to registration of 7 months, against a target of 3 months (range: 4 to 14 months). Of the industry respondents (<i>n</i> = 13), 61.5% indicated the initiative had had a positive impact on their business, though expectations were only met to some degree (31%-46%). Failure to create a less expensive process and to facilitate simultaneous multiple market access (31% and 23% respectively) were the most common unmet expectations. Nonetheless, 62% of the industry respondents expressed willingness to continue utilising the collaborative process. The cost per joint assessment recommendation during the study period was USD 2,768.</p><p><strong>Conclusion: </strong>The study also highlighted that implementation of initiatives could take time and that some goals can only be achieved in the medium to long term. This is a lesson for other collaboration initiatives in Africa, such as the African Medicines Agency.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2490565"},"PeriodicalIF":3.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12024501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving efficiency in hospital pharmacy systems: the case for color-coded zones for rapidly dispensed medications.","authors":"Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Moyad Shahwan, Faris El-Dahiyat, Abeer M Al-Ghananeem","doi":"10.1080/20523211.2025.2493169","DOIUrl":"https://doi.org/10.1080/20523211.2025.2493169","url":null,"abstract":"<p><p>Colour-coded zones for rapidly dispensed medications are a simple, yet game-changing solution to improve the efficiency and safety of hospital pharmacy systems. This approach integrates visual ergonomics, staff training, and technology in solving some of the most common challenges in medication retrieval and general healthcare delivery. This evidence-based system will go a long way in helping hospitals meet the ever-increasing demands. While colour-coded zoning schemes offer a practical and cost-effective way to enhance pharmacy efficiency and medication safety, their effectiveness depends on careful implementation, standardisation, and integration with digital tools. Although highly digitalised healthcare systems may rely more on automated inventory tracking and barcode verification, colour coding remains a valuable supplementary measure, particularly in fast-paced clinical environments. For resource-limited healthcare facilities, colour-coded zoning serves as an essential safety mechanism where advanced IT solutions may not be feasible. However, standardisation challenges, risks of over-reliance, and accessibility concerns for colour-blind individuals must be addressed to maximise effectiveness. Ultimately, an optimal pharmacy management system may involve a hybrid approach that integrates both visual and digital verification methods, ensuring both efficiency and patient safety across diverse healthcare settings.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2493169"},"PeriodicalIF":3.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12024495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of medication reconciliation on discrepancies and all-cause readmission among hospitalised patients with chronic kidney disease: a quasi-experimental study.","authors":"Shoroq M Altawalbeh, Nahlah M Sallam, Osama Y Alshogran, Minas Al-Khatib, Mohammad S Bani Amer, Linda Tahaineh, Abla Albsoul-Younes","doi":"10.1080/20523211.2025.2488173","DOIUrl":"https://doi.org/10.1080/20523211.2025.2488173","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) with its associated comorbidities and pill burden can expose patients to a heightened risk of drug-related problems, including medication discrepancies. This study aimed to evaluate the impact of medication reconciliation supplemented with medication review on the number of medication discrepancies at discharge and all-cause readmission among CKD patients.</p><p><strong>Methods: </strong>This was a quasi-experimental trial among adult CKD patients admitted into two major referral hospitals in northern Jordan. Patients in the intervention group received medication reconciliation supplemented with medication review by a clinical pharmacist, while those in the control group received the usual care. The recognised discrepancies were evaluated at admission and at discharge in both groups. Participants were followed for 90-day readmission.</p><p><strong>Results: </strong>Among patients in the intervention group, the average number of discrepancies was 2.5 ± 2.2 per CKD patient. Compared to the control group, the reduction in discrepancy numbers between admission and discharge was higher in the intervention group by 1.66 discrepancies. The likelihood of 90-day readmission was significantly lower in the intervention group (OR = 0.41; <i>P</i> = 0.002).</p><p><strong>Conclusion: </strong>Supplemented medication reconciliation among CKD patients reveals a favourable impact on medication discrepancies and readmission rates. Optimising medication management during transitions of care can improve overall health outcomes.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2488173"},"PeriodicalIF":3.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of pharmacists in enhancing epilepsy care: a systematic review of community and outpatient interventions.","authors":"Michael Petrides, Aliki Peletidi, Evangelia Nena, Theodoros Constantinidis, Christos Kontogiorgis","doi":"10.1080/20523211.2025.2487046","DOIUrl":"https://doi.org/10.1080/20523211.2025.2487046","url":null,"abstract":"<p><strong>Background: </strong>Approximately 50 million individuals across the globe are impacted by epilepsy, leading to fear, discrimination, psychiatric issues, high costs, and social stigma. Proper diagnosis and treatment could allow up to 70% of those affected to live seizure-free. Community pharmacists have significant potential to actively participate in epilepsy patient care, beyond merely dispensing medications. The objective of this study was to systematically review and assess the roles of pharmacists in epilepsy care, focusing on pharmacist-led interventions and services for patients with epilepsy.</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, the review included cross-sectional, retrospective cohort, and qualitative/quantitative studies on pharmacist-led epilepsy interventions in community and outpatient settings. Searches were conducted in Scopus, PubMed Central, and Science Direct for studies published through the end of 2023. Two evaluators independently reviewed and chose studies, and the data was analysed using Microsoft Excel®. Quality assessment was performed using the MMAT tool.</p><p><strong>Results: </strong>Five eligible studies were included, covering 457 participants. Studies originated from the USA (<i>n</i> = 3), Netherlands (<i>n</i> = 1), and Palestine (<i>n</i> = 1). They evaluated pharmacist-led interventions in epilepsy, including medication adherence, quality of life, and pharmacist's integration in epilepsy care.</p><p><strong>Conclusion: </strong>This review underscores the possible contributions of pharmacists in epilepsy care, stressing the importance of pharmacist-led interventions to enhance medication adherence and the quality of life for individuals with epilepsy. Future research should evaluate the effectiveness and cost-effectiveness of these services, including disease management and patient education. Increasing awareness among pharmacists and patients about pharmacists' contributions is crucial for improving epilepsy care.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2487046"},"PeriodicalIF":3.3,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine.","authors":"Natalia Bilousova","doi":"10.1080/20523211.2025.2484577","DOIUrl":"https://doi.org/10.1080/20523211.2025.2484577","url":null,"abstract":"<p><p><b>Background:</b> According to WHO's data, a significant number of deaths from CVD is observed in Ukraine. In today's conditions, the problems of ensuring the availability of medicines and pharmaceutical care for patients with CHD and comorbid conditions are being addressed at all levels of management of the Ukrainian healthcare sector in conditions of limited funds, resources and martial law. The scientific development of a conceptual model for providing pharmaceutical care to such patients, aimed at reducing the burden on the healthcare system and ensuring the safe use of medicines in compliance with European legislation, is highly relevant. <b>Methods:</b> The methods used in this work include information retrieval, analysis, synthesis, generalisation, induction and deduction, synergistic, dialectical, and modelling. <b>Results:</b> The conceptual model of pharmaceutical care for patients with CHD and comorbid conditions was developed and substantiated. The place and role of pharmacists in the context of participation in interprofessional collaboration in multidisciplinary teams is defined. The rationale for involving pharmacists in multidisciplinary teams has been substantiated, as this will enhance the quality of personalised care, prevent potential medicines interactions considering their metabolic profiles, reduce the risk of adverse reactions and improve patient adherence to pharmacotherapy. <b>Conclusion:</b> The model of pharmaceutical care for patients with CHD and comorbid conditions takes into account the cardiovascular continuum and pharmacotherapy, which will lead to a decrease in disease progression, pharmacotherapeutic risks, reduce the burden on the healthcare system and guarantee the safety of medicines use. Implementation of the conceptual model of pharmaceutical care for patients with CHD and comorbid conditions in pharmaceutical practice requires revision of educational training programmes.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2484577"},"PeriodicalIF":3.3,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-reporting of adverse drug reactions of nonsteroidal anti-inflammatory drugs in community pharmacies.","authors":"Phayom Sookaneknun Olson, Janet Krska, Chatmanee Taengthonglang, Pinyapat Tansin, Wilasinee Siangtrong, Piyatida Pongrueangdilok, Narumol Jarernsiripornkul, Pemmarin Potisarach","doi":"10.1080/20523211.2025.2483419","DOIUrl":"https://doi.org/10.1080/20523211.2025.2483419","url":null,"abstract":"<p><strong>Background: </strong>Ibuprofen and diclofenac are nonsteroidal anti-inflammatory drugs widely used worldwide. Spontaneous reporting often results in an underestimation of the incidence of adverse drug reactions (ADRs), and a few studies have been conducted in community settings, particularly in community pharmacies. This study aimed to determine the frequency and characteristics of short-term ADRs associated with ibuprofen and diclofenac in community pharmacy patients.</p><p><strong>Methods: </strong>This prospective cohort study was conducted in 15 community pharmacies. A questionnaire from a previous study was modified and tested for content validity. Community pharmacists distributed the questionnaire after dispensing ibuprofen or diclofenac and followed non-responders via telephone and online media platforms. The returned questionnaires were assessed for causality by a pharmacist and three researchers. Descriptive analyses and comparisons between reports on ibuprofen and diclofenac were performed using chi-square and independent t-tests for appropriate outcomes.</p><p><strong>Results: </strong>Of the 590 distributed questionnaires, 279 were included in the analysis. The percentage of participants who reported ADRs to ibuprofen and diclofenac was 33.3%. Among participants with suspected ADRs, the average number of suspected ADRs from diclofenac was higher than from ibuprofen; however, no significant difference was observed (5.5 ± 8.9 and 3.1 ± 3.0, <i>p</i> > 0.05). Of the 347 self-reported ADRs, 45.2% were assessed as probable and possible ADRs. The highest rate of suspected ADRs was in Mental Health (14.4%), followed by the Nose, Throat, Neck, or Voice (9.8%), and the Stomach or Digestive Systems (8.9%), respectively.</p><p><strong>Conclusions: </strong>Diclofenac showed more suspected ADRs than ibuprofen in a community setting. Almost half of the self-reported ADRs were assessed as probable or possible. Strategies for sustaining community pharmacists in monitoring patients and reporting ADRs should be supported.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2483419"},"PeriodicalIF":3.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database.","authors":"Dongdong Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Wei Wang, Wenhui Wang, Chengfu Cai","doi":"10.1080/20523211.2025.2479072","DOIUrl":"10.1080/20523211.2025.2479072","url":null,"abstract":"<p><strong>Background: </strong>This study's main goal was to closely monitor and record adverse events (AEs) related to the medication Etelcalcetide, which is used to treat secondary hyperparathyroidism (SHPT, which is defined as elevated parathyroid hormone (PTH) levels in response to abnormalities in the calcium, phosphate, and vitamin D homeostasis). Optimising patient safety and offering evidence-based recommendations for the proper use of this medication are the ultimate goals.</p><p><strong>Methods: </strong>A thorough collection and analysis of reports from the FDA Adverse Event Reporting System (FAERS) database was conducted, encompassing the first quarter of 2014 to the first quarter of 2024. Robust algorithms including as ROR, PRR, BCPNN, and EBGM were employed for proportional analysis, enabling efficient data mining to measure signals linked to AEs related to Etelcalcetide.</p><p><strong>Results: </strong>Based on the reports gathered, the number of patients in the Etelcalcetide population was found to be 2,472 (5,435 AEs). As expected, the study's findings revealed the occurrence of Decreased blood calcium, Hypophosphatemia, among other AEs, which are in line with the instructions in the medication insert. Furthermore, unforeseen major AEs were noted at the preferred term (PT) level. These included hunt stenosis, Shunt aneurysm, Shunt occlusion, Shunt infection and Peripheral arterial occlusive disease (PAOD) and so on. These results point to the possibility of AEs that are not presently listed in the medication description.</p><p><strong>Conclusion: </strong>This work successfully identified previously unidentified and novel signals linked to AEs associated with the administration of Etelcalcetide, offering crucial insights into the intricate relationship between AEs and Etelcalcetide use. In the context of Etelcalcetide therapy, the study's findings highlight the vital significance of diligent surveillance and ongoing monitoring for the prompt detection and efficient management of AEs and to enhance overall patient safety and well-being.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2479072"},"PeriodicalIF":3.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, attitude, and perception regarding the respiratory syncytial virus vaccine among healthcare professionals.","authors":"Khawla Abu Hammour, Qusai Al Manaseer, Mariam Abdel-Jalil, Faris El-Dahiyat, Walid Abu Hammour, Adnan M Abu Hammour, Fahmi Y Al-Ashwal, Rana Abu-Farha","doi":"10.1080/20523211.2025.2482669","DOIUrl":"10.1080/20523211.2025.2482669","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a significant respiratory pathogen. Despite vaccine availability, uptake remains low, and healthcare professionals play a key role in promoting immunisation. This study aims to evaluate healthcare providers' knowledge, perceptions and practices regarding the RSV vaccine.</p><p><strong>Methods: </strong>A validated survey was distributed to healthcare professionals. The study questionnaire contained sections to assess sociodemographic characteristics, knowledge of RSV and its vaccines, healthcare professionals' perception towards RSV and its vaccines, and their perception towards the potential barriers against RSV vaccination. The last section assesses physicians' previous practice in dealing with RSV infection.</p><p><strong>Results: </strong>Over half of the participants (56.6%) had no prior awareness of RSV, though many recognised its potential severity, particularly in vulnerable populations like children and older adults (52.6%). Awareness of FDA-approved RSV vaccines was limited, with only 28.1% of respondents familiar with vaccines intended for older adults. Views on vaccination recommendations for older age groups were divided; 23.7% supported vaccination for those 75 and older, while 31.1% advocated for vaccination in those aged 60-74 at higher risk. Perceived barriers to RSV vaccination were prominent. Most respondents (85.1%) cited concerns about vaccine safety as a key obstacle, and 81.1% identified out-of-pocket costs as a significant barrier. Testing for RSV was infrequent (24.6%), mainly due to a lack of effective treatment. Most participants (96.9%) called for greater awareness and education about RSV vaccines, and 91.2% supported recommending the vaccine if it was available and free.</p><p><strong>Conclusion: </strong>This study reveals significant gaps in healthcare professionals' knowledge and practices regarding RSV and its vaccines, with substantial barriers to vaccine adoption. Targeted education, improved diagnostics, and addressing vaccine barriers are essential strategies for improving the healthcare response to RSV.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2482669"},"PeriodicalIF":3.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine handling practices and conformity to cold chain temperature requirements in selected regions of Tanzania: a descriptive cross-sectional study.","authors":"Wema Kibanga, Castory Munishi, Hafidhi Ntissi, Pacifique Ndayishimiye, David T Myemba, Elirehema Mfinanga, Ritah F Mutagonda, Eliangiringa Kaale","doi":"10.1080/20523211.2025.2479062","DOIUrl":"10.1080/20523211.2025.2479062","url":null,"abstract":"<p><strong>Background: </strong>Poor handling practices and infrastructures for vaccine management, especially in remote rural areas, pose a challenge to the accessibility of safe and efficacious vaccines. This study assessed vaccine handling practices and conformity to cold chain systems in Tanzania.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from March 2022 to October 2022 using temperature loggers, checklists and questionnaires adopted from the WHO Vaccine Management Assessment Tool. The study sites were 35 facilities in Dar es salaam, Kigoma and Mtwara regions in Tanzania. Data was analysed by R statistical software.</p><p><strong>Results: </strong>A total of 89 vaccine handling personnel with 22 personnel of less than 30 years old were included in this study. Seventy vaccine-handling personnel out of a total of 89 had adequate knowledge and 63 participants had good vaccine-handling practices. Fifty-three participants had no prior training in vaccine handling. Most (80%) of the facilities visited complied with the WHO cold chain storage standard of 2°C to 8°C in one month of observation; however, 29 facilities did not have temperature alarms to alert in cases of temperature changes and 24 facilities had no voltage regulators.</p><p><strong>Conclusion: </strong>In this study, most of the facilities studied were compliant with WHO vaccine storage temperature requirements over a 30-day period. However, significant gaps were identified, including inadequate infrastructure for emergency situations and a lack of prior training on vaccine handling among the majority of personnel.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2479062"},"PeriodicalIF":3.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformative pharmacy and health innovations: advancing sustainable solutions for global health challenges.","authors":"Tashya Dhela Maylinda, Dini Permata Sari, Linawaty, Farisa Luthfiana","doi":"10.1080/20523211.2025.2472537","DOIUrl":"10.1080/20523211.2025.2472537","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 Suppl 1","pages":"2472537"},"PeriodicalIF":3.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}